Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient care.
It focuses on the needs of cardiologists and primary care clinicians, but is also applicable to providers
at all levels. is Guideline should not be considered exclusive of other methods of care reasonably
directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of
conduct must be made by the clinician aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated with
the distributor of this clinical reference tool.
ACCHF16063g
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Copyright © 2016 All rights reserved
Source
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, Drazner MH, Filippatos G,
Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE,
Peterson PN, Stevenson LW, Westlake C, 2016 ACC/AHA/HFSA Focused Update on New
Pharmacological erapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for
the Management of Heart Failure, Journal of the American College of Cardiolog y (2016),
doi: 10.1016/j.jacc.2016.05.011.
To access the digital or mobile version of this guideline for free,
or to sign up to be notified when the full guideline update is released,
visit GuidelineCentral.com/HFupdate
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080
©2016 Novartis Printed in the USA 6/16 ETR-1332369
